Outcome in peripartum cardiomyopathy after heart transplantation.
From 1983 to 1991, 27 women with peripartum cardiomyopathy were considered for heart transplantation. Of 27 patients, 11 (41%) improved with medical therapy, 10 (37%) underwent transplantation, and six (22%) died. Results in the 10 patients with peripartum cardiomyopathy who underwent transplantation were compared with results in 39 women who underwent transplantation for dilated cardiomyopathy (idiopathic, Adriamycin, valvular, or familial) to determine whether there were differences in survival, rejection, or infection rates. The two groups were, by chance, well matched for number of pregnancies, peak panel reactivity, and cross-match. Mean time from delivery to transplantation was 24 weeks (range 2 to 188 weeks), and this time did not correlate with rejection rates. The linearized rate of rejection from 0 to 3 months was 30% higher in the group with peripartum cardiomyopathy (3.4 +/- 0.7 vs 2.6 +/- 0.3 episodes/100 patient days; p = 0.05). The mean postoperative day to first rejection was day 26 for peripartum cardiomyopathy and day 28 for women with dilated cardiomyopathy. Rejection requiring cytolytic therapy occurred in 40% of women with peripartum cardiomyopathy and 21% of the comparison group (difference not significant). Linearized (treated) infection rates were 1.8 +/- 0.5 for the group with peripartum cardiomyopathy versus 1.5 +/- 0.2 episodes/100 patient days for others (p = 0.05). Actuarial survival was excellent in both groups with 88% and 86% 2-year survival rates, respectively. In conclusion, women who undergo transplantation for peripartum cardiomyopathy have a 30% higher rate of early rejection than do those who undergo transplantation for idiopathic cardiomyopathy and tend to have a greater need for cytolytic therapy. Infection rates are consequently higher.(ABSTRACT TRUNCATED AT 250 WORDS)
Cardiopulmonary Transplant Unit, St. Vincent's Hospital, Sydney NSW, Australia.
A
A
Keogh
P
P
Macdonald
P
P
Spratt
D
D
Marshman
R
R
Larbalestier
A
A
Kaan
D000206:Actuarial Analysis; D000328:Adult; D000906:Antibodies / Q000032:analysis; D009202:Cardiomyopathies / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D002311:Cardiomyopathy, Dilated / Q000276:immunology / Q000401:mortality / Q000601:surgery; D003327:Coronary Disease / Q000276:immunology / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology* / Q000401:mortality; D006680:HLA Antigens / Q000276:immunology; D006333:Heart Failure / Q000276:immunology / Q000401:mortality / Q000601:surgery; D016027:Heart Transplantation / Q000276:immunology* / Q000401:mortality; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D007165:Immunosuppression Therapy; D008875:Middle Aged; D009894:Opportunistic Infections / Q000276:immunology / Q000401:mortality; D011183:Postoperative Complications / Q000276:immunology* / Q000401:mortality; D011644:Puerperal Disorders / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate
D000906:Antibodies; D006680:HLA Antigens